Proteomics Research of Osteosarcoma
PROS001
Establishment of New Molecular Prototyping Based on Proteomics for Predicting Osteosarcoma Chemotherapy Response and Risk of Recurrence
1 other identifier
observational
400
1 country
1
Brief Summary
Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2018
CompletedFirst Submitted
Initial submission to the registry
April 26, 2019
CompletedFirst Posted
Study publicly available on registry
April 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2020
CompletedMay 2, 2019
April 1, 2019
1 year
April 26, 2019
April 30, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
proteomics changes
Study of changes in proteomes in tumor cells by high-throughput proteomics analysis
2 years
Study Arms (3)
osteosarcoma
chondrosarcoma
enchondroma
Interventions
all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Eligibility Criteria
primary care clinic
You may qualify if:
- all osteosarcoma patients in our hospital
- received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy
You may not qualify if:
- non-chemotherapy patients
- bio-specimen not completed
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
2nd Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310020, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
zhaoming Ye, Prof.
2nd Affiliated Hospital Of Zhejiang University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 26, 2019
First Posted
April 30, 2019
Study Start
September 1, 2018
Primary Completion
September 1, 2019
Study Completion
September 1, 2020
Last Updated
May 2, 2019
Record last verified: 2019-04
Data Sharing
- IPD Sharing
- Will not share